1GA
SLXP

1st Global Advisors’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

1st Global Advisors’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-3,645
Closed -$569K – 500
2014
Q3 		$569K Buy
+3,645
New +$528K 0.09% 177

Other funds holding SLXP

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

1st Global Advisors's SLXP Position: Q4 2014 in Review

1st Global Advisors sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q4 2014, closing a stake of 3,645 shares — an estimated $569K sold.

1st Global Advisors first reported a position in SLXP in Q3 2014 and held it in 1 quarter. The position peaked at $569K in Q3 2014. 347 funds tracked by Wall St. Rank hold SLXP as of Q4 2014.

  • 1st Global Advisors reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q4 2014 after selling out during the quarter.
  • 1st Global Advisors sold 3,645 SALIX PHARMACEUTICALS LTD DEL shares in Q4 2014, an estimated $569K.
  • 1st Global Advisors first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q3 2014 and held it in 1 quarter.
  • 1st Global Advisors's SALIX PHARMACEUTICALS LTD DEL position peaked at $569K in Q3 2014.
  • 347 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q4 2014.

Based on 1st Global Advisors's 13F filing for Q4 2014, filed 27 Jan 2015.